《新股消息》海普瑞药业(09989.HK)明起招股 入场费10,403.8元
已在深圳上市的海普瑞药业(09989.HK)公布招股详情,将於明日(24日)起至下周二(30日)招股,发行约2.2亿股H股,当中本地公开发售占10%。每股招股价介乎18.4至20.6元,每手500股入场费10,403.79元,最多集资45.34亿元,设15%超额配售权。该公司料於7月8日在主板挂牌,由摩根士丹利及高盛担任联席保荐人。
海普瑞将引入5名基石投资者,与上市投资者同设6个月禁售期。集资所得约用於偿还现有债务以改善资本结构、於欧洲及其他市场发展营销网络及基建、提升研发生产能力,以及用於创新药投资。
据招股文件介绍,海普瑞专注於高致死率疾病,业务覆 盖制药领域、生物科技领域及CDMO领域。按2019年全球销售额计,海普瑞是中国最大及全球第三大依诺肝素钠注射液生产商及销售商,占据6.5%的全球市场份额。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.